Accugenomics
Mr. McNeill is a partner with Liberty Healthcare Group in Wilmington, N.C., an integrated post-acute healthcare network providing long-term care, assisted living, home health, and hospice across the Carolinas. From 1988 to 1996, he was a partner with Pharmaceutical Product Development, Inc. (PPDI) in Wilmington, N.C., a Contract Research Organization serving the pharmaceutical industry with Phase 1 through Phase 5, clinical trial management, Pharmacoeconomics, Biostatistics, Informatics, and Genomics. He is a member of the University of North Carolina Wilmington Cameron School of Business Executive Advisory Board and the Wilmington Investor Network, an angel investing group. He has a B.S. in Chemical Engineering from NC State University and an M.B.A. from Georgia State University. He is a registered professional engineer in North Carolina.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Accugenomics
AccuGenomics is a developer of a unique spike-in control technology that dramatically improves the accuracy and performance of clinical sequencing tests for low abundance biomarkers such as circulating tumor DNA (ctDNA) and low titer infectious pathogens such as SARS-CoV-2.